Key statistics
As of last trade ALK-Abello A/S (0OIR:LSE) traded at 156.50, -15.63% below its 52-week high of 185.50, set on Aug 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 156.50 |
Low | 156.50 |
Bid | -- |
Offer | -- |
Previous close | 149.45 |
Average volume | 8.73k |
---|---|
Shares outstanding | 202.57m |
Free float | 112.76m |
P/E (TTM) | 43.98 |
Market cap | 32.27bn DKK |
EPS (TTM) | 3.59 DKK |
Data delayed at least 20 minutes, as of Nov 26 2024 08:00 GMT.
More ▼
- Nine-month interim report (Q3) 2024 (unaudited)
- Nine-month interim report (Q3) 2024 (unaudited) - English version only
- ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
- ALK indlicenserer rettigheder til neffy®, den første godkendte næsespray med adrenalin til akut behandling af allergiske reaktioner (anafylaksi)
- Invitation til præsentation af ALK’s regnskab for de første ni måneder (Q3) 2024 torsdag den 14. november 2024
- Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024
- Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
- Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
- Six-month interim report (Q2) 2024
- Six-month interim report (Q2) 2024 - English version only
More ▼